The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

Derrett-Smith, E; Clark, KEN; Shiwen, X; Abraham, DJ; Hoyles, RK; Lacombe, O; Broqua, P; Junien, JL; Konstantinova, I; Ong, VH; Denton, CP

Journal article

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

Abstract:: Background: The TβRII∆k-fib transgenic (TG) mouse model of scleroderma replicates key fibrotic and vasculopathic complications of systemic sclerosis through fibroblast-directed upregulation of TGFβ signalling. We have examined peroxisome proliferator-activated receptor (PPAR) pathway perturbation in this model and explored the impact of the pan-PPAR agonist lanifibranor on the cardiorespiratory phenotype. Methods: PPAR pathway gene and protein expression differences from TG and WT sex-matched littermate mice were determined at baseline and following administration of one of two doses of lanifibranor (30 mg/kg or 100 mg/kg) or vehicle administered by daily oral gavage up to 4 weeks. The prevention of bleomycin-induced lung fibrosis and SU5416-induced pulmonary hypertension by lanifibranor was explored. Results: Gene expression data were consistent with the downregulation of the PPAR pathway in the TβRII∆k-fib mouse model. TG mice treated with high-dose lanifibranor demonstrated significant protection from lung fibrosis after bleomycin and from right ventricular hypertrophy following induction of pulmonary hypertension by SU5416, despite no significant change in right ventricular systolic pressure. Conclusions: In the TβRII∆k-fib mouse strain, treatment with 100 mg/kg lanifibranor reduces the development of lung fibrosis and right ventricular hypertrophy induced by bleomycin or SU5416, respectively. Reduced PPAR activity may contribute to the exaggerated fibroproliferative response to tissue injury in this transgenic model of scleroderma and its pulmonary complications

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Derrett-Smith, E., Clark, K. E. N., Shiwen, X., Abraham, D. J., Hoyles, R. K., Lacombe, O., Broqua, P., Junien, J. L., Konstantinova, I., Ong, V. H., & Denton, C. P. (2021). The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis. Arthritis Research & Therapy, 23(1), 234–234.

MLA Style

Derrett-Smith, E, et al. “The Pan-PPAR Agonist Lanifibranor Reduces Development of Lung Fibrosis and Attenuates Cardiorespiratory Manifestations in a Transgenic Mouse Model of Systemic Sclerosis.” Arthritis Research & Therapy, vol. 23, no. 1, 2021, pp. 234–34.

Chicago Style

Derrett-Smith, E, KEN Clark, X Shiwen, et al. 2021. “The Pan-PPAR Agonist Lanifibranor Reduces Development of Lung Fibrosis and Attenuates Cardiorespiratory Manifestations in a Transgenic Mouse Model of Systemic Sclerosis.” Arthritis Research & Therapy 23 (1): 234–34.
Print